尿液C-C基序趋化因子配体14(CCL14)预测持续性急性肾损伤的外部验证
本研究为前瞻性多中心SAPPHIRE研究的二次分析,纳入入组一周内发生KDIGO 2-3期AKI的心脏和/或呼吸功能障碍危重患者195例,在AKI 2-3期起病时检测尿液CCL14浓度。主要终点为持续性严重AKI(KDIGO 3期AKI持续≥72小时,或72小时前死亡或接受肾脏替代治疗),28例(14%)发生。尿液CCL14预测持续性严重AKI的AUC为0.81(95%CI 0.72-0.89),且CCL14三分位越高,持续性严重AKI风险及90天RRT和/或死亡风险越高。该二次分析外部验证了尿液CCL14对危重患者持续性严重AKI的预测价值。
要点
- 心脏和/或呼吸功能障碍危重患者发生KDIGO 2-3期AKI时,尿液CCL14预测持续性严重AKI的AUC为0.81(95%CI 0.72-0.89)。
- 195例KDIGO 2-3期AKI患者中28例(14%)发生持续性严重AKI,其中15例AKI≥72小时、12例接受RRT、1例在KDIGO 3期AKI≥72小时前死亡。
- 持续性严重AKI与慢性肾脏病、糖尿病、更高的非肾脏APACHE III评分、更大的液体平衡、使用血管升压药及更大的基线血清肌酐变化相关。
- 尿液CCL14值越高,持续性严重AKI风险越高;90天RRT和/或死亡风险随尿液CCL14浓度三分位升高而增加。
适用人群与场景
- 前瞻性多中心SAPPHIRE研究中发生心脏和/或呼吸功能障碍的危重患者,且在入组一周内发生KDIGO 2-3期AKI。
诊断标准与关键阈值
- 持续性严重AKI定义:KDIGO 3期AKI持续≥72小时,或72小时前死亡或接受肾脏替代治疗(RRT)。
研究设计与关键结果
- 研究类型:前瞻性多中心SAPPHIRE研究的二次分析;样本量195例发生KDIGO 2-3期AKI的危重患者。
- 主要终点:28例(14%)发生持续性严重AKI,其中15例AKI≥72小时、12例接受RRT、1例在KDIGO 3期AKI≥72小时前死亡。
- 持续性严重AKI与慢性肾脏病、糖尿病、更高的非肾脏APACHE III评分、更大的液体平衡、使用血管升压药及更大的基线血清肌酐变化相关。
- 尿液CCL14预测持续性严重AKI的AUC为0.81(95%CI 0.72-0.89)。
- 尿液CCL14值越高,持续性严重AKI风险越高;90天RRT和/或死亡风险随尿液CCL14浓度三分位升高而增加。
证据类型、等级与局限
- 证据类型:前瞻性多中心研究的二次分析(外部验证)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论:该二次分析外部验证了尿液CCL14可预测危重患者持续性严重AKI。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Persistent acute kidney injury (AKI) portends worse clinical outcomes and remains a therapeutic challenge for clinicians. A recent study found that urinary C-C motif chemokine ligand 14 (CCL14) can predict the development of persistent AKI. We aimed to externally validate urinary CCL14 for the prediction of persistent AKI in critically ill patients.
METHODS: This was a secondary analysis of the prospective multi-center SAPPHIRE study. We evaluated critically ill patients with cardiac and/or respiratory dysfunction who developed Kidney Disease: Improving Global Outcomes (KDIGO) stage 2-3 AKI within one week of enrollment. The main exposure was the urinary concentration of CCL14 measured at the onset of AKI stage 2-3. The primary endpoint was the development of persistent severe AKI, defined as ≥ 72 h of KDIGO stage 3 AKI or death or renal-replacement therapy (RRT) prior to 72 h. The secondary endpoint was a composite of RRT and/or death by 90 days. We used receiver operating characteristic (ROC) curve analysis to assess discriminative ability of urinary CCL14 for the development of persistent severe AKI and multivariate analysis to compare tertiles of urinary CCL14 and outcomes.
RESULTS: We included 195 patients who developed KDIGO stage 2-3 AKI. Of these, 28 (14%) developed persistent severe AKI, of whom 15 had AKI ≥ 72 h, 12 received RRT and 1 died prior to ≥ 72 h of KDIGO stage 3 AKI. Persistent severe AKI was associated with chronic kidney disease, diabetes mellitus, higher non-renal APACHE III score, greater fluid balance, vasopressor use, and greater change in baseline serum creatinine. The AUC for urinary CCL14 to predict persistent severe AKI was 0.81 (95% CI, 0.72-0.89). The risk of persistent severe AKI increased with higher values of urinary CCL14. RRT and/or death at 90 days increased within tertiles of urinary CCL14 concentration.
CONCLUSIONS: This secondary analysis externally validates urinary CCL14 to predict persistent severe AKI in critically ill patients.
参考来源
- Bagshaw SM, Al-Khafaji A, Artigas A, et al. External validation of urinary C-C motif chemokine ligand 14 (CCL14) for prediction of persistent acute kidney injury. Crit Care. 2021. PMID: 34059102. doi:10.1186/s13054-021-03618-1
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。